Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018-January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32-43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34-38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.

Original publication

DOI

10.2807/1560-7917.ES.2019.24.1900121

Type

Journal article

Journal

Euro Surveill

Publication Date

02/2019

Volume

24

Keywords

Europe, influenza, multicentre study, test-negative design, vaccination, vaccine effectiveness, vaccines and immunisation, Adolescent, Adult, Aged, Case-Control Studies, Child, Europe, Female, Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus, Influenza Vaccines, Influenza, Human, Male, Middle Aged, Outcome Assessment, Health Care, Population Surveillance, Primary Health Care, Reverse Transcriptase Polymerase Chain Reaction, Seasons, Sensitivity and Specificity, Vaccination, Vaccine Potency